Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK PLC Sponsored ADR stock logo
GSK
GSK
$49.68
+0.9%		$50.84
$40.36
▼
$61.69
$99.60B0.352.80 million shs3.56 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK PLC Sponsored ADR stock logo
GSK
GSK
+0.79%-2.87%-2.20%-5.25%+24.74%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
GSK PLC Sponsored ADR stock logo
GSK
GSK
$49.68
+0.9%		$50.84
$40.36
▼
$61.69
$99.60B0.352.80 million shs3.56 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
GSK PLC Sponsored ADR stock logo
GSK
GSK
+0.79%-2.87%-2.20%-5.25%+24.74%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
GSK PLC Sponsored ADR stock logo
GSK
GSK
2.09
Hold$56.5013.72% Upside

Current Analyst Ratings Breakdown

Latest GSK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/15/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$60.00
9/15/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Berenberg Bank logo
Berenberg Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Buy
9/10/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
9/8/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform ➝ Sector Perform
8/25/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingUnderweight
7/30/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
7/29/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
7/24/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral
7/17/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/9/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
GSK PLC Sponsored ADR stock logo
GSK
GSK
$43.07B2.33$6.06 per share8.20$10.32 per share4.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
GSK PLC Sponsored ADR stock logo
GSK
GSK
$7.54B$3.2015.549.862.0614.56%43.23%11.60%10/28/2026 (Estimated)

Latest GSK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/28/2026Q2 2026 & Strategy update
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.27$1.36+$0.09$0.28$11.02 billion$11.14 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
GSK PLC Sponsored ADR stock logo
GSK
GSK
$1.783.58%-7.86%55.63%N/A

Latest GSK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2026
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.45153.65%8/14/20268/14/202610/8/2026
1/1/2100
GSK PLC Sponsored ADR stock logo
GSK
GSK
quarterly$0.42064.3%8/15/20258/15/202510/9/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
GSK PLC Sponsored ADR stock logo
GSK
GSK
0.81
0.82
0.52

Institutional Ownership

CompanyInstitutional Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
15.74%

Insider Ownership

CompanyInsider Ownership
GSK PLC Sponsored ADR stock logo
GSK
GSK
10.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
GSK PLC Sponsored ADR stock logo
GSK
GSK
66,8412.02 billion1.82 billionOptionable

Recent News About These Companies

GSK to Acquire Trispecific T Cell-Engager for Multiple Myeloma from Chimagen Biosciences
September 28 at 3:05 PM  |  jdsupra.comhttps://www.jdsupra.com/legalnews/gsk-to-acquire-trispecific-t-cell-3181009/
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
September 28 at 1:26 PM  |  zacks.comhttps://www.zacks.com/stock/news/2996969/merck-daiichi-withdraw-fda-filing-for-lung-cancer-therapy?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2996969
GSK PLC Sponsored ADR (NYSE:GSK) Stock Has Consensus Price Target of $56.50
September 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31047295
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of "Hold" from Brokerages
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-gsk-plc-sponsored-adr-nyse-gsk-receives-consensus-rating-of-hold-from-brokerages-2026-09-25/
GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-bets-hutchmed-expand-multi-205949512.html
GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger?
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-adds-another-cancer-drug-224147376.html
Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/berenberg-turns-bullish-gsk-750-230854693.html
$3.3 Million in New Philanthropic Commitments for Good Jobs Western North Carolina from The Rockefeller Foundation, John M. Belk Endowment, and NC GSK Foundation
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/economy/policy/articles/3-3-million-philanthropic-commitments-110000615.html
Analyzing BioAge Labs (NASDAQ:BIOA) & GSK (NYSE:GSK)
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31044598
Defend all jobs at GSK’s Dresden vaccine plant in Germany!
September 23, 2026  |  wsws.orgW
GSK plc (GSK) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
September 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949183-gsk-plc-gsk-presents-at-bernstein-insights-healthcare-leaders-and-disruptors-3rd-annual
GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-gsk-bets-on-long-acting-biologics-and-ai-to-reshape-respiratory-care-2026-09-23/
GSK plc (GSK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
September 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4948941-gsk-plc-gsk-presents-at-bank-of-america-global-healthcare-conference-2026-transcript
GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape
September 23, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-gsk-targets-40b-sales-as-oncology-push-and-19b-savings-plan-take-shape-2026-09-23/
GSK stock gains on Berenberg upgrade and steady pipeline momentum
September 19, 2026  |  ad-hoc-news.deA
This week in charts: GSK’s China deals, the $300M IPO club and selling the news
September 19, 2026  |  biopharmadive.comB
ViiV Healthcare Partners with Prevention Access Campaign (PAC) to Celebrate 10 Years of U=U and Look to The Future
September 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/viiv-healthcare-partners-prevention-access-120000512.html
Baird Financial Group Inc. Buys 26,290 Shares of GSK PLC Sponsored ADR $GSK
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-baird-financial-group-inc-buys-26290-shares-of-gsk-plc-sponsored-adr-gsk-2026-09-17/
GSK (LSE:GSK) Agrees Multiple Myeloma T Cell Deal
September 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/gsk-lse-gsk-agrees-multiple-011220850.html
GSK to Acquire Chimagen's Trispecific Cancer Drug in Deal Worth Up to USD 750 Mn
September 16, 2026  |  medicaldialogues.inM
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-gsk-targets-oncology-growth-with-lung-prostate-and-gynecologic-cancer-pipeline-2026-09-16/

New MarketBeat Followers Over Time

Media Sentiment Over Time

GSK stock logo

GSK NYSE:GSK

$49.68 +0.44 (+0.90%)
Closing price 09/28/2026 03:59 PM Eastern
Extended Trading
$50.36 +0.68 (+1.36%)
As of 07:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas